[Pion radiotherapy of unresectable soft tissue sarcomas at the Swiss Institute for Nuclear Research].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Thum P;Thum P; Greiner R; Blattmann H; Coray A; Zimmermann A
  • Source:
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] [Strahlenther Onkol] 1988 Dec; Vol. 164 (12), pp. 714-23.
  • Publication Type:
    English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    German
  • Additional Information
    • Transliterated Title:
      Pionen-Strahlentherapie nichtresektabler Weichteilsarkome am schweizerischen Institut für Nuklearforschung (SIN).
    • Source:
      Publisher: Urban & Vogel Country of Publication: Germany NLM ID: 8603469 Publication Model: Print Cited Medium: Print ISSN: 0179-7158 (Print) Linking ISSN: 01797158 NLM ISO Abbreviation: Strahlenther Onkol Subsets: MEDLINE
    • Publication Information:
      Original Publication: [München] : Urban & Vogel, [c1986-
    • Subject Terms:
      Sarcoma/*radiotherapy ; Soft Tissue Neoplasms/*radiotherapy; Adolescent ; Adult ; Aged ; Female ; Humans ; Male ; Mesons ; Middle Aged ; Pelvic Neoplasms/radiotherapy ; Radiotherapy, High-Energy ; Retroperitoneal Neoplasms/radiotherapy
    • Abstract:
      The Swiss Institute for Nuclear Research SIN at Villigen is one of the three centres in the world (LAMPF, Los Alamos; TRIUMF, Vancouver) where pion therapy is possible. A dynamic, tumour conforming spot scan technique for the treatment of deep-seated tumours has been in use since November 1981. With this technique with a favorable integral dose distribution, curative irradiation also of advanced tumours in the retroperitoneum and pelvis is possible. Only at SIN, the treatment of non-resectable soft tissue sarcomas with pions is part of the clinical program. Between 1983 and 1985 totally nine patients were treated, 1/9 with three manifestations, 1/9 with palliative intent. In 20 fractions over five weeks (four fractions a week) total doses of 30 to 36 Gy (90% isodose) were applied. In a follow-up period of eleven to 43 months (median 18 months) only 1/10 tumour manifestations treated with greater than or equal to 30 Gy failed locally. The two-year survival rate (Kaplan-Meier) is 56%. Metastases were the cause of death in 3/5 patients, 1/5 heart disease, 1/5 local tumour progression. Even though 9/11 tumours were located in the retroperitoneum or pelvis, no radiogenic morbidity of the bowel was found. These preliminary results stimulate the intensification of this clinical program. 1986 the same number of patients with non-resectable soft tissue sarcomas was treated as in the whole period 1982 to 1985 before.
    • Publication Date:
      Date Created: 19881201 Date Completed: 19890209 Latest Revision: 20061115
    • Publication Date:
      20240829
    • Accession Number:
      3144761